A B S T R A C T Prolactin secretion in normal adults is characterized by periods of episodic secretion which increase in magnitude during sleep. In this study, we report the 24-h mean prolactin concentrations, prolactin secretory patterns, and associated pituitary hormone function in nine patients (seven women and two men) with hyperprolactinemia of diverse etiologies. Four of the women and one of the men had clinically demonstrable pituitary tumors, one boy had a hypothalamic tumor, and the three other women had "functional" hyperprolactinemia. The 24-h mean prolactin concentrations derived from averaging the 20-min interval samples for 24 h ranged from 28.6 to 1,220 ng/ml. The plasma prolactin patterns in these patients showed persistence of episodic secretion in all and loss of the normal sleepwake difference in plasma prolactin in seven of nine. Three of the patients with galactorrhea and comparable 24-h mean prolactin concentrations (58.3, 59.7, and 64.3 ng/ml) showed similar prolactin secretory patterns despite different etiologic mechanisms. Evaluation of the secretory patterns of luteinizing hormone (LH) in these patients showed loss of normal pulsatile LH release and a low 24-h mean LH concentration in the patient with the pituitary tumor, while the two patients without clinically demonstrable pituitary tumors ("post-pill" galactorrhea and "idiopathic" galactorrhea) showed normal LH secretory patterns and 24-h mean LH concentrations. The 24-h mean cortisol concentrations and secretory patterns were normal in five of the seven patients who had these parameters measured. The patient with the hypothalamic tumor had a low 24-h mean cortisol concentration and production rate and absent response to metyrapone. The patient with "idiopathic" galactorrhea had an elevated 24-h mean cortisol concentration but normal cortisol production rate and urinary 17-hydroxycorticoid excretion. Growth hormone secre- 
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hypothalamic tumor and three with pituitary tumors). Thyrotropin-releasing hormone (TRH) administration in four patients resulted in normal TSH release in two patients (one of whom developed galactorrhea after the test), an absent response in the patient with the hypothalamic tumor, and a blunted response in one of the women with a pituitary tumor. The two men had low 24- (1) (2) (3) (4) (5) (6) (7) (8) and in disease statesally throughout the day and night has greatly clarified and extended our knowledge of the physiological regulation of these hormones. Measurement of plasma hormone concentrations during sleep has proven to be especially important for hGH (29) , LH (30) , and follicle-stimulating hormone (FSH) during puberty (31) and most recently hPRL (32) . In 1972, Nokin, Vekemans, L'Hermite, and Robyn (33) showed the episodicity of hPRL concentrations with peak values at 1 a.m. and 5 a.m. when sampling was carried out at 4-h intervals. Sassin, Frantz, Weitzman, and Kapen (32) showed the important role of sleep in the regulation of hPRL secretion in normal young adults of both sexes. The finding of episodicity and sleep-associated augmentation of hPRL secretion has been further clarified by recent studies (34, 35) .
The present study concerns the 24-h pattern of hPRL secretion in some hyperprolactinemic patients. Plasma hPRL concentrations were measured at 20-min intervals for 24-h in nine patients with hyperprolactinemia from a variety of causes: five with pituitary tumors, one with a hypothalamic tumor, and three with "functional" 2 hyperprolactinemia (Table I) . In order to evaluate the frequency and nature of associated disturbances in the hypothalamic-pituitary regulation of the secretion of other hormones, measurements were also made of LH, testosterone (in the two males), and cortisol levels (every 20 min for 24-h), control and thyrotropin-releasing hormone (TRH)-stimulated plasma thyroid-stimulating hormone (TSH) levels, control and metyraponestimulated urinary 17-hydroxycorticoid excretion, and control and stimulated (by insulin, arginine, and/or sleep) plasma hGH levels. The results of these studies show that: (a) seven of our nine patients with hyperprolactinemia had excessive diurnal hPRL secretion, disturbing the normal difference between preponderant sleep-related secretory episodes and those of wakefulness; (b) no differences were observed between the patterns of hPRL secretion in patients with hyperprolactinemia of "functional" origin to distinguish them from patients with pituitary or hypothalamic tumors; and (c) the normal pattern of secretion of hGH, LH, and TSH was more frequently affected in patients with clinically demonstrable tumors than in those patients with "functional" hyperprolactinemia.
METHODS

Subjects
Nine patients (seven women and two men) with hyperprolactinemia were studied ( (26, 30, 31) . GH (37) , TSH (38) , cortisol (39) , and testosterone (40) were assayed by previously reported techniques. Cortisol production rate was estimated by isotope dilution (41) , and urinary 17-hydroxycorticoids (42) and 17-ketosteroids (43) were measured by standard methods. Plasma hPRL was measured by a homologous radioimmunoassay utilizing reagents supplied by the NIAMD. 2 ,ug of highly purified human PRL (Lewis hPRL, 30 IU/mg) were iodinated with 400 ,oCi of 'I (Union Carbide Corp., New York) according to the method of Hunter and Greenwood (44) . Purification was achieved by passing the iodinated raw mixture over Sephadex G-100 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.). Three peaks were identified, and only the middle peak, which contained immunoreactive hPRL, was used for immunoassay. The anti-hPRL antibody (rabbit) was used at a dilution of 1: 200,000. The hPRL was diluted with buffer to a concentration of 200 ng/ml, and standards were prepared by appropriate dilution to concentrations of 0.25, 0.50, 1.0, 1.5, 2.5, 3.75, and 5.0 ng/ml. Parallel standard curves were obtained with the hPRL standard and multiple dilutions of plasma from a patient with galactorrhea. Known quantities of standard hPRL were recovered quantitatively. Specificity studies of the anti-hPRL antibody were previously reported (8) .
The anti-hPRL antibody was diluted in 0.01 M Na phosphate buffer, pH 7.6, containing 0.14 M NaCl, 0.05 M EDTA, and 3%o normal rabbit serum at a final dilution of 1: 200,000 in each assay tube. The [I51]hPRL (10, 000 cpm) was diluted in 0.01 M Na phosphate buffer, pH 7.6, containing 0.14 M NaCl and 0.1% bovine serum albumin (BSA). Plasma samples in normal subjects were assayed at 100 ,l in duplicate and at 25 ,d in duplicate in the patients with moderately elevated plasma hPRL concentrations (50-100 ng/ml). In the patients with marked elevations of plasma hP-RL, plasma was diluted 1:10 with 1% BSA 8 "Post-pill" or "post contraceptive amenorrhea-galactorrhea" refers to those women in whom amenorrhea galactorrhea occurred in close temporal association to the withdrawal of oral contraceptives. The * Mean prolactin asleep significantly (P < 0.001) higher than mean prolactin awake.
buffer, and 50-Al. aliquots of the diluted material were assayed. This dilution permitted the most sensitive part of the standard curve to be used for the assay and produced results indistinguishable when compared with results obtained by dilution using plasma from a hypophysectomized patient. The total volume in each reaction tube was adjusted to 500 ,l by the appropriate addition of 0.01 M Na phosphate buffer, pH 7.6, containing 0.14 M NaCl and 1% BSA.
After 72 h incubation at 4°C, 200 ,ul of goat-antirabbit gamma globulin appropriately diluted in buffer was added to precipitate maximally the antigen-antibody complex in each reaction tube. 24 h later, the tubes were centrifuged at 1,000 g for 30 min, the supernates were decanted, and the precipitates were counted in an automatic gamma counter. Total counts were checked for consistency in tubes throughout the assay. Results were calculated from dose interpolation of the standards by using logit-log transformation. The interassay precision for a plasma assayed in nine different assays was 11.1±2.1 (SD) ng/ml. All samples from each 24-h study were assayed simultaneously to negate interassay variability.
Special studies L-Dopa test. L-Dopa (0.5 g) was given orally between 9 and 11 a.m., and plasma hPRL concentrations were measured at 30- Metyrapone test. After two base-line 24-h urine collections, 750 mg metyrapone was given orally every 4 h for six doses, and urine 17-hydroxycorticoids and 17-ketosteroids were measured on the base-line days, day of metyrapone administration, and day after metyrapone administration.
Cortisol metabolism.
[14C] cortisol was injected intravenously to determine production rate, half-life, and metabolic clearance rate of cortisol by methods previously reported from this laboratory (23, 41) .
Mean hormone concentrations. By averaging all 72 results obtained during the course of a 20-min interval 24-h study for hPRL, LH, cortisol, and testosterone in the males, the 24-h mean hormone concentrations were obtained. The mean cortisol concentration obtained by this method compares favorably with that obtained with the constant withdrawal pump (45) . Mean plasma hPRL concentrations during sleep and awake periods were calculated by averaging the results which fell within these respective periods.
Comparison of the mean plasma hPRL concentrations calculated from plasmas obtained from patients asleep and awake were used to assess the presence of the normal sleep-associated augmentation of hPRL secretion. Statistical analyses were performed by using Student's t test, to establish the loss of the sleep-associated augmented hPRL secretion. (Table II ). All nine patients had significantly elevated 24-h mean plasma hPRL concentrations, ranging from 28.6±5.8 (SD) ng/ ml to 1,220±219 (SD) ng/ml. Every patient continued to show episodic secretion of hPRL throughout the 24-h period (Figs. 1-3) . However, the normal increase of hPRL concentrations during sleep was lost in seven of the nine patients; levels were elevated and equal during the sleeping and waking periods. significantly higher mean hPRL concentrations during sleep than while awake. Comparison of the 24-h pattern of hPRL secretion in the tumor patients with those of patients with "functional" hyperprolactinemia showed no specific characteristics that could be used to distinguish one group from the other. LH concentration (Table III) . The 24-h mean LH concentration was somewhat low in four of the patients with pituitary tumors (3.5-5.6 mIU/ml; normal, 10.2± 3.8 in women and 7.2±3.2 in men). Both men (cases 1 and 7) had low LH concentrations in relation to their prepubertal plasma testosterone concentrations. Clomiphene citrate, 50 mg twice daily, given orally for 6 wk in case 1 and 7 days in case 7, resulted in a normal rise in LH and testosterone in case 1 but no response in case 7. The three women with "functional" hyperprolactinemia had normal mean LH concentrations (7.5-10.3 mIU/ml). Cases 2 and 3 with "functional" hyperprolactinemia (Figs. 2, 3 ) also showed normal LH secretory patterns compared with normal women (46) ; however, in case 9 with the Chiari-Frommel synhPRL levels and large standard deviations suggest cautious interpretation of this difference.
RESULTS
Plasma prolactin concentrations
drome there was abnormal suppression of LH secretion during sleep.
Thyroid function (Table IV) . All nine patients were clinically euthyroid and had normal plasma thyroxine concentrations by radioassay. Three of the four who were tested had normal 24-h 1"I uptakes; the fourth (with the hypothalamic tumor) had a slightly low uptake of 10% (47) . Administration of TRH (500 Ag i.v.) to four patients showed a normal TSH rise in two (one with a pituitary tumor and one with "functional" hyperprolactinema), a blunted TSH response in one (with a pituitary tumor), and no response in one (with the hypothalamic tumor). In the patient with the pituitary tumor who showed a normal response (case 5), the test precipitated persistent galactorrhea which eventually remitted after radiotherapy. This side effect of the TRH test has been unusual in our experience, although others (48) have reported resumption of lactation in women who had stopped nursing for several days after TRH administration.
GH reserve (Table IV) . Four of the nine patients (three with pituitary tumors and the one with a hypothalamic tumor) showed subnormal hGH reserve, i.e. failure of hGH to rise above 7 ng/ml either during 1592 Boyar et al.
stage III, IV sleep, in response to arginine infusion, in response to insulin hypoglycemia, or all three. ACTH-cortisol function (Table IV) . The 24-h mean cortisol concentration was measured in seven of the nine patients. It was very low (1.6 ug/100 ml) in the patient with the hypothalamic tumor but was essentially normal in the other six patients, (perhaps slightly high, 9.5 ug/100 ml in one patient with "functional" hyperprolactinemia). Cortisol production rates were measured in six of these seven patients and one other patient; they were normal in every case except the hypothalamic tumor patient in whom it was very low (2.4 mg g creatinine 24 h). This patient also had very low 17-hydroxy--corticoids which failed to rise sufficiently in response to metyrapone (but did respond to ACTH). The other eight patients had normal 17-hydroxycorticoids. The five patients with pituitary tumors tested with metyrapone had normal responses.
Interrelation of LH and hPRL secretory activity (Figs.  2 and 3 ). In the three women with "functional" hyperprolactinemia and normal 24-h mean LH concentrations, a suggestive reciprocal relationship could be identified between the initiation of LH and hPRL secretory episodes. Fig. 2 shows that the peaks of the three major LH secretory episodes occurring during the night coincided with nadirs of the corresponding hPRL concentrations or cessation of secretory activity. For example, when LH secretory activity is quiescent (Fig. 2, 0900 -1400 h) hPRL secretion occurs. In Fig. 3 formed at the termination of her 24-h study) are shown in Fig. 1 . Although episodic release persists after the administration of L-dopa, the amplitude of the hPRL secretory episodes appears to decrease when compared to the corresponding clocktimes during the preceding day. These three patients with galactorrhea of diverse etiologies all showed significant suppression of the plasma hPRL concentration after L-dopa administration. DISCUSSION The hyperprolactinemic patients studied comprised six with tumors (five pituitary and one hypothalamic) and three with "functional" disorders (one with the ChiariFrommel syndrome, one with "post-contraceptive" amenorrhea-galactorrhea, and one with "idopathic" galactorrhea). Five of the six patients with clinically demonstrable tumors and two of the three patients with "functional" hyperprolactinemia (the one with "postcontraceptive" amenorrhea-galactorrhea and the one with "idiopathic" galactorrhea) showed a loss of the normal sleep augmentation of hPRL secretion; hPRL levels were elevated but equal during the sleeping and waking periods. The two hyperprolactinemic patients with the Chiari-Frommel syndrome ( patients. This abnormality of hPRL secretion, viz. elevated 24-h mean, peak, and minimal plasma concentrations and loss of sleep augmentation, is very reminiscent of the abnormality of the cortisol secretory pattern that is seen in Cushing's disease6 (50). Krieger and Glick (51 ) suggested, on the basis of the latter findings, that Cushing's disease is a disorder of hypothalamic regulation of hormonal secretion. They found confirmation of the postulated hypothalamic dysfunction by demonstrating strikingly subnormal GH secretory reserve in patients with Cushing's disease, whether or not a clinically demonstrable pituitary adenoma was present. The present study of patients with hyperprolactinemia also shows a high frequency (Table V) of deficient secretory reserve for the other hypothalamic-pituitary-regulated hormones (7/9 for LH, 4/9 for GH, 2/9 for TSH, and 1/9 for ACTH-cortisol function). In contrast with Krieger's findings in Cushing's disease, however, the associated hormonal secretory defects in hyperprolactinemia were almost uniformly found in the patients with tumors and were essentially ' The observation of a temporal reciprocal relationship between the initiation of hPRL secretion and cessation or a decrease in the pulsatile secretion of LH in some of our hyperprolactinemic patients supports the conclusion from experiments in rats that a dopaminergic mechanism controls the secretion of these two hormones.
Kamberi, Mical, and Porter (52, 53) showed that dopamine injected into the third ventricle causes a rise in LH-releasing factor and a rise in PRL-inhibiting factor in the hypophyseal portal circulation. The finding of complete cessation of pulsatile LH secretion during the nocturnal hours when hPRL secretion was maximal in case 9 with the Chiari-Frommel syndrome suggests that a similar mechanism may be operative in man (48) . These results as well as the frequency with which amenorrhea is associated with galactorrhea suggests that the elevated hPRL levels per se may exert a direct effect on the normal hypothalamic regulation of LH and FSH secretion. The finding that hyperprolactinemic patients show normal LH and FSH responses to the gonadotropin-releasing hormone (54) and clomiphene citrate (case 1) supports this view. The clinical observations that suppression of elevated hPRL levels medically with 2-bromoa-ergocryptine (CB 154) results in suppression of galactorrhea and concomitant resumption of normal menses (55) provide additional evidence that elevated 0.001) than mean hPRL awake.
hPRL levels may exert a direct effect on the normal secretion of LH and FSH. Since all three of our patients with "functional" hyperprolactinemia had normal TSH, hGH, and ACTH-cortisol function, an important direct effect of elevated hPRL levels on the hypothalamic regulation of these hormones appears unlikely.
